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Dear Editor,
The article published in Hepatitis Monthy on non-
invasive assessment of liver fibrosis with the aspartate 
transaminasis to platelet ratio index (APRI) in patients 
with chronic liver disease by Yilmaz et al. (1), is interest-
ing and very useful to permit a diagnosis and staging of 
fibrosis, although this index does not seem to have a high 
sensitivity and specificity. In recent years, efforts have 
been made to develop non-invasive predictive models 
that may correlate with stage of fibrosis. One of the first 
non-invasive predictive models for patients with chron-
ic hepatitis C (CHC) was the Fibrotest, which includes 
α2-macroglobulin, haptoglobin, γ-glutamil-transferase 
(GGT), apolipoprotein A1 and total bilirubin. However, 
considerable expenses and use of uncommon param-
eters reduce their clinical applicability. A few years later, 
the Forns’ score (age, GGT, cholesterol, platelets and pro-
thrombin) and the APRI index (AST and platelets) over-
came these draw-backs by use of only standard labora-
tory tests in the development of their predictive models. 
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Subsequent models include the ELF-score, the Hepascore 
and the Fibrometer (2). Thus, actually, the models of non-
invasive predictors of liver fibrosis can be divided into 
two main groups: models only consisting of simple rou-
tine tests (the S index, Hui model, Forns’ score and APRI) 
and models including special tests such hyaluronic acid 
and serum α2-macroglobulin (the SLFG model, Fibrome-
ter and Hepascore) (3).
Yilmaz Y et al., found that the APRI was significantly as-
sociated with fibrosis scores in patients with CHC and 
NAFLD, but not in those with CHB. Nevertheless, CHB 
is the most frequent infectious cause of chronic liver 
disease worldwide. More than 400 million people are 
chronically infected with HBV. The virus is responsible 
for more than 300,000 cases of liver cancer annually (4). 
Thus, it is relevant to find more significant approaches to 
the diagnosis of fibrosis in CHB. Recently, Zhou K et al. (2), 
compared different non-invasive methods to assess liver 
fibrosis and found that the S index was not only signifi-
cantly associated with fibrosis in CHB patients, but it also 
had the highest predictive value in assessing significant 
fibrosis, compared with other analyzed models.
The S index is based on routine laboratory markers 
such as γ-glutamiltransferase, platelets count and albu-
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min (GGT, PLT and ALB) that are readily available to most 
clinicians managing patients with chronic HBV infec-
tion, so that no additional tests are needed. Moreover, it 
seems that AST, one of the two parameters considered in 
the APRI, did not show a significant correlation with liv-
er fibrosis staging of CHB patients, determining a lower 
sensibility of APRI than S index. In fact, they found that in 
predicting significant fibrosis in CHB patients the sensi-
tivity was 81% for S index and 71 % for APRI, and in predict-
ing advanced fibrosis the sensitivity of the two models 
increased up to 89% for the S index and 81% for APRI. For 
detecting liver fibrosis in CHC, CHB and NAFLD patients, 
authors reported that APRI has a sensitivity of 72.2% 
and a specificity of 62.4% for the diagnosis of fibrosis in 
CHC patients; 60% and 62.4%, respectively for the NAFLD 
group; and 55% and 75.4%, respectively for CHB patients. 
These data state that physicians cannot make their diag-
nosis of liver fibrosis only based on APRI, and biopsy is 
necessary for the diagnosis and staging of fibrosis. There-
fore, it would be interesting to investigate the potential 
usefulness of other non-invasive tests such as liver stiff-
ness measurement (LSM), FIB-4 (5) and FORNS biochem-
istry (6) indices as well as transient elastography (7), that 
showed in literature better sensitivity and specificity. 
Although most of the non-invasive predictive models 
are not able to give the exact staging of fibrosis due to 
serious overlap among patients with different stages of 
fibrosis, they have sufficient accuracy in predicting sig-
nificant fibrosis in various liver diseases (8, 9). Further-
more, the combination of diagnostic models and other 
non-invasive techniques can improve the performance 
to a higher level. The combined use of transient elastog-
raphy and Fibro test to evaluate liver fibrosis could avoid 
a biopsy procedure in most patients with CHC (10). Com-
bination of Fibroscan and S index will also an effective 
way of managing CHB patients, especially in the follow-
up of antiviral therapy.
The detection and staging of liver fibrosis is surely cru-
cial for management of patients with chronic liver dis-
ease. At present, liver biopsy is the gold standard method 
for staging fibrosis, but biopsies are poorly tolerated 
because they are invasive and associated with some dis-
comfort and complications. In addition, limitations of 
biopsy include intra- and inter-observer variation and 
sampling error (2). For all these reasons, we agree that 
it is necessary to find out new, reliable, and non-invasive 
diagnostic methods for identifying patients with liver fi-
brosis. Nevertheless, before implementing a model into 
practice, priority should be given to large scale valida-
tion studies.
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